[BRIEFING.COM] The tech-heavy Nasdaq (-0.5%) continues to trade a step behind the benchmark S&P 500 (-0.3%).
Biotechnology names have struggled today, sending the iShares Nasdaq Biotechnology ETF (IBB 302.19, -7.89) to a three-month low. Heavyweights like Gilead Sciences (GILD 70.38, -2.48), Celgene (CELG 98.97, -2.17), and Biogen (BIIB 308.30, -7.41) show losses between 2.1% and 3.3%. Meanwhile, the IBB is lower by 2.5%.
The health care sector, which houses biotechnology names, is still trading in second place on the 2017 sector leaderboard, as it has done for the vast majority of the year, with a year-to-date gain of 17.2%. However, that gain has been trimmed noticeably since hitting a peak in late October, when the group was up 21.5% for the year.